Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.
Adenocarcinoma
/ diagnosis
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor
Esophageal Neoplasms
/ diagnosis
Female
Gene Expression
Humans
Immunohistochemistry
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ genetics
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Proportional Hazards Models
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
revised:
31
08
2020
accepted:
02
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
9
7
2021
Statut:
epublish
Résumé
Indoleamine 2,3-dioxygenase (IDO) is an interferon-inducible immune checkpoint expressed on tumor-infiltrating lymphocytes (TILs). IDO is known as a poor prognostic marker in esophageal squamous cell cancer, while a positive effect was shown for breast cancer. A comprehensive analysis of IDO expression in a well-defined cohort of esophageal adenocarcinoma (EAC) is missing. We analyzed 551 patients with EAC using single-protein and multiplex immunohistochemistry as well as mRNA in situ technology for the expression and distribution of IDO on subtypes of TILs (INF- IDO expression on TILs was seen in up to 59.6% of tumors, and expression on tumor cells was seen in 9.2%. We found a strong positive correlation of IDO-positive TILs, CD3-positive T lymphocytes, and INF- Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.
Sections du résumé
BACKGROUND
BACKGROUND
Indoleamine 2,3-dioxygenase (IDO) is an interferon-inducible immune checkpoint expressed on tumor-infiltrating lymphocytes (TILs). IDO is known as a poor prognostic marker in esophageal squamous cell cancer, while a positive effect was shown for breast cancer. A comprehensive analysis of IDO expression in a well-defined cohort of esophageal adenocarcinoma (EAC) is missing.
METHODS
METHODS
We analyzed 551 patients with EAC using single-protein and multiplex immunohistochemistry as well as mRNA in situ technology for the expression and distribution of IDO on subtypes of TILs (INF-
RESULTS
RESULTS
IDO expression on TILs was seen in up to 59.6% of tumors, and expression on tumor cells was seen in 9.2%. We found a strong positive correlation of IDO-positive TILs, CD3-positive T lymphocytes, and INF-
CONCLUSIONS
CONCLUSIONS
Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.
Identifiants
pubmed: 33029538
doi: 10.1155/2020/2862647
pmc: PMC7527882
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2862647Informations de copyright
Copyright © 2020 Heike Loeser et al.
Déclaration de conflit d'intérêts
All authors declare that they have no conflict of interest.
Références
Oncotarget. 2018 May 04;9(34):23482-23493
pubmed: 29805749
Methods Mol Med. 2005;114:257-68
pubmed: 16156109
J Thorac Oncol. 2019 Jul;14(7):1266-1276
pubmed: 30978502
Br J Cancer. 2020 Jan;122(1):30-44
pubmed: 31819194
Ann Surg. 2007 Feb;245(2):241-6
pubmed: 17245177
Gynecol Oncol. 2010 Jun;117(3):423-8
pubmed: 20350764
FEBS Lett. 2007 Apr 3;581(7):1449-56
pubmed: 17367785
Cytokine Growth Factor Rev. 2016 Oct;31:73-81
pubmed: 27502919
Clin Cancer Res. 2007 Dec 1;13(23):6993-7002
pubmed: 18056175
Front Immunol. 2018 Jan 31;9:151
pubmed: 29445380
Int J Cancer. 2015 Sep 1;137(5):1095-106
pubmed: 25683635
Sci Rep. 2016 Feb 18;6:21319
pubmed: 26887337
Int J Mol Sci. 2017 Dec 28;19(1):
pubmed: 29283429
J Cell Biochem. 2018 Jul;119(7):5028-5042
pubmed: 29327370
Food Chem Toxicol. 2018 Sep;119:380-386
pubmed: 29475041
Histopathology. 2018 Jul;73(1):124-136
pubmed: 29489025
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Chin Med J (Engl). 2017 Mar 20;130(6):710-716
pubmed: 28303855
Clin Cancer Res. 2011 Oct 1;17(19):6118-24
pubmed: 21705455
J Clin Med. 2018 Feb 19;7(2):
pubmed: 29463006
BMC Med. 2012 May 29;10:51
pubmed: 22642691
Adv Exp Med Biol. 2017;1036:129-144
pubmed: 29275469
J Immunother Cancer. 2015 Dec 15;3:51
pubmed: 26674411
Cancer Res. 2018 Feb 1;78(3):809-816
pubmed: 29118088
Clin Cancer Res. 2016 Sep 1;22(17):4328-40
pubmed: 26979392
Target Oncol. 2018 Apr;13(2):125-140
pubmed: 29302770
Expert Rev Vaccines. 2012 Nov;11(11):1315-7
pubmed: 23249231
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052
Ann Surg. 2015 Nov;262(5):817-22; discussion 822-3
pubmed: 26583671
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Oncotarget. 2016 Apr 19;7(16):21763-74
pubmed: 26943575
World J Surg. 2010 Apr;34(4):738-43
pubmed: 20098986
Ann Surg. 2008 Dec;248(6):902-8
pubmed: 19092334
Int J Cancer. 2012 Jan 1;130(1):96-104
pubmed: 21328335
Nat Clin Pract Urol. 2005 Aug;2(8):416-22
pubmed: 16482653
Cancer Immunol Immunother. 2013 May;62(5):829-37
pubmed: 23344392
Cancer Res. 2017 Dec 15;77(24):6795-6811
pubmed: 29247038
Transl Oncol. 2018 Apr;11(2):426-435
pubmed: 29475139
Front Immunol. 2018 Jul 11;9:1598
pubmed: 30050535
Front Immunol. 2018 Apr 17;9:724
pubmed: 29719533